Kiniksa Pharmaceuticals, Ltd. (KNSA) closed the last trading session at $24.47, gaining 1.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $34.83 indicates a 42.3% upside potential. The mean estimate comprises six short-term price targets with a standard deviation of $3.92. While the lowest estimate of $30 indicates a 22.6% increase from the current price level, the most optimist ...

Core Viewpoint - The article emphasizes the importance of identifying and sustaining trends in short-term investing, highlighting that sound fundamentals and positive earnings estimates are crucial for maintaining momentum in stock prices [1]. Group 1: Stock Performance - Kiniksa Pharmaceuticals, Ltd. (KNSA) has shown a solid price increase of 41.2% over the past 12 weeks, indicating strong investor interest [3]. - The stock has maintained a price increase of 0.2% over the last four weeks, suggesting that the upward trend is still intact [4]. - KNSA is currently trading at 87.9% of its 52-week high-low range, indicating a potential breakout opportunity [4]. Group 2: Fundamental Strength - KNSA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises [5]. - The stock has an Average Broker Recommendation of 1 (Strong Buy), reflecting high optimism from the brokerage community regarding its near-term price performance [6]. Group 3: Investment Strategy - The article suggests that investors can utilize the "Recent Price Strength" screen to identify stocks like KNSA that are on an uptrend with strong fundamentals [2]. - There are over 45 Zacks Premium Screens available for investors to find stocks that align with their personal investing styles [7].

Core Viewpoint - Kiniksa Pharmaceuticals will participate in the 2024 Wells Fargo Healthcare Conference, indicating ongoing engagement with investors and the healthcare community [1]. Company Overview - Kiniksa Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing therapeutic medicines for patients with significant unmet medical needs [3]. - The company’s immune-modulating assets include ARCALYST®, abiprubart, and mavrilimumab, which target underserved cardiovascular and autoimmune conditions [3]. - Kiniksa aims to differentiate its products based on strong biological rationale and validated mechanisms [3]. Event Details - The fireside chat is scheduled for September 4, 2024, at 8:00 a.m. Eastern Time, showcasing the company's commitment to transparency and investor relations [1]. - A live webcast of the presentation will be available on Kiniksa's website, with a replay accessible within approximately 48 hours post-event [2].

Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, aiming to capitalize on established directions for profitable trades [1] Company Performance - Kiniksa Pharmaceuticals, Ltd. (KNSA) shares have increased by 33.69% over the past quarter and 39.98% over the last year, significantly outperforming the S&P 500, which moved 7.34% and 19.81% respectively [2] - KNSA's consensus earnings estimate improved from -$0.10 to -$0.05 over the past 60 days, with one upward revision and no downward revisions for the current fiscal year [3] Momentum Indicators - KNSA has a Momentum Score of B and is rated as a 1 (Strong Buy) stock, indicating strong potential for near-term gains [4][6] - The stock's short-term price activity shows a 0.09% increase over the past week, while the Zacks Medical - Biomedical and Genetics industry declined by 1.81% during the same period [9] - KNSA's monthly price change of 39.38% outperforms the industry's 5.35% performance [9] Trading Volume - KNSA's average 20-day trading volume is 684,469 shares, which serves as a bullish indicator when combined with rising stock prices [10] Estimate Revisions - The Zacks Momentum Style Score incorporates trends in estimate revisions, which have been positive for KNSA, indicating potential for continued performance [11]

Core Viewpoint - The article emphasizes the importance of identifying sustainable trends in short-term investing, highlighting Kiniksa Pharmaceuticals, Ltd. (KNSA) as a strong candidate for trend investing due to its recent price performance and fundamental strength [1][9]. Group 1: Price Performance - KNSA has experienced a solid price increase of 33.7% over the past 12 weeks, indicating strong investor interest [3]. - The stock is currently trading at 85.7% of its 52-week high-low range, suggesting it may be on the verge of a breakout [4]. - Over the past four weeks, KNSA's price has increased by 39.4%, confirming that the upward trend is still intact [10]. Group 2: Fundamental Strength - KNSA holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises [11]. - The stock also has an Average Broker Recommendation of 1 (Strong Buy), indicating high optimism from the brokerage community regarding its near-term price performance [12]. Group 3: Investment Strategy - The "Recent Price Strength" screen is a useful tool for identifying stocks like KNSA that have the fundamental strength to maintain their uptrend [2]. - The Zacks Rank stock-rating system has a proven track record, with Zacks Rank 1 stocks generating an average annual return of +25% since 1988, suggesting that KNSA's price trend may continue positively [5].

The Company evenly splits profits on sales of ARCALYST with Regeneron, where profits are determined after deducting from net sales of ARCALYST certain costs related to the manufacturing and commercialization of ARCALYST. Such costs include but are not limited to (i) the Company's cost of goods sold for product used, sold or otherwise distributed for patient use by the Company; (ii) customary commercialization expenses, including the cost of the Company's field force, and (iii) the Company's cost to market, ...

Company Performance - Kiniksa Pharmaceuticals reported a quarterly loss of $0.06 per share, better than the Zacks Consensus Estimate of a loss of $0.09, compared to a loss of $0.02 per share a year ago [1] - The company posted revenues of $108.63 million for the quarter, surpassing the Zacks Consensus Estimate by 23.68%, and compared to year-ago revenues of $71.47 million [11] - Over the last four quarters, Kiniksa has surpassed consensus EPS estimates two times and topped consensus revenue estimates four times [2][11] Market Comparison - Kiniksa Pharmaceuticals shares have increased by approximately 22% since the beginning of the year, outperforming the S&P 500's gain of 16.7% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.02 on revenues of $99.65 million, and -$0.10 on revenues of $380.84 million for the current fiscal year [5] - The company is expected to post a quarterly loss of $0.42 per share in its upcoming report, reflecting a year-over-year change of -16.7% [6] Estimate Revisions - The estimate revisions trend for Kiniksa Pharmaceuticals is mixed, leading to a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market in the near future [9] Industry Context - Kiniksa Pharmaceuticals operates within the Zacks Medical - Biomedical and Genetics industry, which is currently in the top 33% of over 250 Zacks industries [14]

2023 | --- | --- | --- | --- | |-------|-------|----------------------------|-------| | | | | | | | | Second Quarter 2024 | | | | | Financial Results and | | | | | Recent Portfolio Execution | | JULY 23, 2024 | --- | --- | --- | --- | |-------|-------|----------------------------|-------| | | | | | | | | Second Quarter 2024 | | | | | Financial Results and | | | | | Recent Portfolio Execution | | Agenda | --- | --- | |---------------------------------------------------------------------------------|-------| ...

[Overview and Highlights](index=1&type=section&id=Overview%20and%20Highlights) Kiniksa reported strong Q2 2024 results, raising ARCALYST revenue guidance and advancing abiprubart's Phase 2b trial Q2 2024 Key Highlights | Metric | Q2 2024 Value | Year-over-Year Growth | | :--- | :--- | :--- | | ARCALYST Net Product Revenue | $103.4 million | 90% | - Raised full-year 2024 ARCALYST net product revenue guidance to **$405 - $415 million**, up from the previous range of **$370 - $390 million**[18](index=18&type=chunk)[22](index=22&type=chunk)[26](index=26&type=chunk) - The company expects to maintain annual cash flow positivity[18](index=18&type=chunk)[22](index=22&type=chunk)[26](index=26&type=chunk) - Clinical development for abiprubart in Sjögren's Disease is fully funded within the current operating plan, and the Phase 2b trial is enrolling patients[18](index=18&type=chunk)[22](index=22&type=chunk) [Portfolio Execution](index=1&type=section&id=Portfolio%20Execution) Strong ARCALYST commercial performance with increasing patient penetration and therapy duration, alongside active abiprubart Phase 2b trial enrollment [ARCALYST (rilonacept)](index=1&type=section&id=ARCALYST%20%28rilonacept%29) - ARCALYST net product revenue was **$103.4 million** for the second quarter of 2024[18](index=18&type=chunk) - As of Q2 2024, approximately **11%** of the **14,000** target patients with multiple-recurrence pericarditis were on ARCALYST, up from **~9%** at the end of 2023[18](index=18&type=chunk)[23](index=23&type=chunk) - The average total duration of ARCALYST therapy for recurrent pericarditis increased to approximately **26 months**, up from **~23 months** in Q1 2024[18](index=18&type=chunk)[23](index=23&type=chunk) - Since its launch in April 2021, over **2,300** prescribers have written ARCALYST prescriptions for recurrent pericarditis[18](index=18&type=chunk) - Kiniksa has sponsored the American Heart Association's 'Addressing Recurrent Pericarditis' initiative and partnered with NHL Hall-of-Famer Henrik Lundqvist to raise awareness[23](index=23&type=chunk) [Abiprubart](index=2&type=section&id=Abiprubart) - Kiniksa is currently enrolling patients in a Phase 2b clinical trial to evaluate the efficacy and safety of abiprubart in patients with Sjögren's Disease[24](index=24&type=chunk) [Financial Performance](index=2&type=section&id=Financial%20Performance) Kiniksa's Q2 2024 revenue grew to $108.6 million, resulting in a net loss due to increased expenses, while maintaining a strong cash position [Financial Results (Q2 2024)](index=2&type=section&id=Financial%20Results%20%28Q2%202024%29) Q2 2024 vs. Q2 2023 Financial Comparison (in millions) | Metric | Q2 2024 | Q2 2023 | | :--- | :--- | :--- | | Total Revenue | $108.6 | $71.5 | | Total Operating Expenses | $108.7 | $74.6 | | Net Income (Loss) | $(3.9) | $15.0 | - Collaboration expenses, driven by ARCALYST profitability, increased to **$30.0 million** in Q2 2024 from **$14.0 million** in Q2 2023[25](index=25&type=chunk) - As of June 30, 2024, Kiniksa had **$218.8 million** in cash, cash equivalents, and short-term investments, with no debt[25](index=25&type=chunk)[13](index=13&type=chunk) [Financial Guidance (Full Year 2024)](index=2&type=section&id=Financial%20Guidance%20%28Full%20Year%202024%29) ARCALYST 2024 Net Product Revenue Guidance (in millions) | Guidance | Amount | | :--- | :--- | | Previous Guidance | $370 - $390 | | Updated Guidance | $405 - $415 | - Kiniksa reaffirms its expectation to remain cash flow positive on an annual basis[26](index=26&type=chunk)[9](index=9&type=chunk) [Financial Statements](index=6&type=section&id=Financial%20Statements) Detailed financial statements show significant year-over-year revenue growth and increased costs, with a healthy cash position and stable shareholders' equity [Consolidated Statements of Operations](index=6&type=section&id=Consolidated%20Statements%20of%20Operations) Selected Consolidated Statements of Operations (In thousands, Unaudited) | | Three Months Ended June 30, | Six Months Ended June 30, | | :--- | :--- | :--- | | | **2024** | **2023** | **2024** | **2023** | | **Total revenue** | **$108,631** | **$71,473** | **$188,489** | **$119,818** | | Product revenue, net | $103,394 | $54,495 | $182,279 | $97,154 | | **Total operating expenses** | **$108,748** | **$74,627** | **$205,148** | **$134,168** | | Cost of goods sold | $12,322 | $7,699 | $22,905 | $14,735 | | R&D | $24,017 | $23,767 | $50,351 | $38,939 | | SG&A | $42,395 | $29,175 | $81,077 | $58,220 | | **Loss from operations** | **$(117)** | **$(3,154)** | **$(16,659)** | **$(14,350)** | | **Net income (loss)** | **$(3,908)** | **$14,972** | **$(21,612)** | **$2,702** | | **Net income (loss) per share—diluted** | **$(0.06)** | **$0.21** | **$(0.31)** | **$0.04** | [Consolidated Balance Sheet Data](index=6&type=section&id=Consolidated%20Balance%20Sheet%20Data) Selected Consolidated Balance Sheet Data (In thousands, Unaudited) | | As of June 30, 2024 | As of December 31, 2023 | | :--- | :--- | :--- | | Cash, cash equivalents, and short-term investments | $218,758 | $206,371 | | Working capital | $216,730 | $212,631 | | Total assets | $542,428 | $526,322 | | Total shareholders' equity | $435,095 | $438,839 | [Corporate and Product Information](index=3&type=section&id=Corporate%20and%20Product%20Information) Kiniksa is a commercial-stage biopharmaceutical company with immune-modulating assets, including ARCALYST and investigational abiprubart [About Kiniksa](index=3&type=section&id=About%20Kiniksa) - Kiniksa is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for debilitating diseases with significant unmet medical need[29](index=29&type=chunk) - The company's key immune-modulating assets include ARCALYST, abiprubart, and mavrilimumab, which target a range of cardiovascular and autoimmune conditions[29](index=29&type=chunk) [About ARCALYST](index=3&type=section&id=About%20ARCALYST) - ARCALYST is a weekly, subcutaneously injected recombinant fusion protein that blocks interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β) signaling[19](index=19&type=chunk) - It is FDA-approved for recurrent pericarditis, cryopyrin-associated periodic syndromes (CAPS), and deficiency of IL-1 receptor antagonist (DIRA)[19](index=19&type=chunk) [About Abiprubart](index=4&type=section&id=Abiprubart) - Abiprubart is an investigational humanized monoclonal antibody designed to inhibit the CD40-CD154 interaction, a key co-stimulatory signal in T-cell and B-cell immune responses[15](index=15&type=chunk) - This mechanism is considered an attractive approach for addressing multiple autoimmune disease pathologies[15](index=15&type=chunk) [Important Safety Information and Forward-Looking Statements](index=3&type=section&id=Important%20Safety%20Information%20and%20Forward-Looking%20Statements) The company provides important safety warnings for ARCALYST and includes forward-looking statements subject to significant risks [Important Safety Information about ARCALYST](index=3&type=section&id=Important%20Safety%20Information%20about%20ARCALYST) - ARCALYST can lower the immune system's ability to fight infections, and serious, life-threatening infections have occurred[20](index=20&type=chunk) - Treatment should be stopped if a serious infection develops[20](index=20&type=chunk) - Concomitant use with other IL-1 blockers or TNF blockers is not recommended as it may increase the risk of serious infection[20](index=20&type=chunk) - Other risks include potential for cancer, allergic reactions, and changes in blood cholesterol and triglycerides[28](index=28&type=chunk) - Common side effects include injection-site reactions and upper respiratory tract infections[28](index=28&type=chunk) [Forward-Looking Statements](index=4&type=section&id=Forward-Looking%20Statements) - The press release contains forward-looking statements concerning ARCALYST revenue guidance, funding for abiprubart development, and expectations of being cash flow positive[9](index=9&type=chunk) - These statements are not guarantees and involve known and unknown risks and uncertainties, such as clinical trial delays, inability to replicate results, and reliance on third-party suppliers[11](index=11&type=chunk) - Readers are cautioned not to place undue reliance on these statements and are directed to the company's SEC filings for a full discussion of risks[12](index=12&type=chunk)

Portfolio Execution ARCALYST (IL-1α and IL-1β cytokine trap) LONDON, July 23, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) (Kiniksa), a commercial-stage biopharmaceutical company with a pipeline of immunemodulating assets designed to target a spectrum of cardiovascular and autoimmune diseases, today reported second quarter 2024 financial results and recent portfolio execution. ARCALYST net product revenue was $103.4 million for the second quarter of 2024. Since launch in ...